This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OptimizeRx (OPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, OptimizeRx (OPRX) closed at $15, marking a -0.73% move from the previous day.
Top Ranked Growth Stocks to Buy for June 28th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 28th
Red Hat's (RHT) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Red Hat's (RHT) first-quarter fiscal 2020 results benefit from strengthening subscription revenues and solid momentum with large deals.
The Zacks Analyst Blog Highlights: Malibu Boats, MEDIFAST, OptimizeRx, Synergy Resources and Pioneer Natural
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Malibu Boats, MEDIFAST, OptimizeRx, Synergy Resources and Pioneer Natural
Brokers Just Love These 5 Stocks
by Sejuti Banerjea
Here are 5 stocks you should buy right now.
Open Text (OTEX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Open Text (OTEX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights: OptimizeRx, eHealth, Strategic Education, Hibbett Sports and PC-Tel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: OptimizeRx, eHealth, Strategic Education, Hibbett Sports and PC-Tel
5 Stocks Likely to Fly High on Powell's Rate Cut Hint
by Nalak Das
Powell's statement is in sharp contrast to his aggressive monetary stance in 2018 and a steady monetary policy for 2019, which he reaffirmed last month.
The Zacks Analyst Blog Highlights: OptimizeRx, Match, OSI and Marchex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: OptimizeRx, Match, OSI and Marchex
5 Tech Stocks Up in May Despite Stock Market Mayhem
by Nalak Das
Wall Street bull run, which continued in the first four months of this year and recorded the best start in 30 years, halted in May.
OptimizeRx Corporation (OPRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OptimizeRx Corporation (OPRX).
The Zacks Analyst Blog Highlights: OptimizeRx, Match, Cubic, PCTEL and Diodes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: OptimizeRx, Match, Cubic, PCTEL and Diodes
5 Tech Stocks That Popped on Halt of Trade Negotiations
by Nalak Das
Wall Street lost a good chunk of value, which it gained through the bull run in first four months of this year, recorded as the best start in 30 years.
OptimizeRx (OPRX) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings
by Zacks Equity Research
Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings
4 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
New Strong Buy Stocks for June 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday